Ahead of likely approval, ICER finds Geron’s imetelstat is not cost-effective at $250,000 annually
In the lead-up to the likely approval of Geron’s drug to treat certain types of anemia, drug pricing watchdog the Institute for Clinical and Economic Review said Thursday that the drug would not be cost-effective at the potential price of $250,000 per year.
The 112-page draft report also found Geron’s imetelstat to be “slightly less costly but also less effective when compared to” Bristol Myers Squibb’s luspatercept, marketed as Reblozyl, to treat patients with myelodysplastic syndromes (MDS), which affect blood cell development and increase the risk of leukemia. With fewer blood cells to transport oxygen through the body, MDS patients often require blood transfusions, which can be costly, time consuming and lead to fatigue.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
